Latest Insider Transactions at Hca Healthcare, Inc. (HCA)
This section provides a real-time view of insider transactions for Hca Healthcare, Inc. (HCA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of HCA Healthcare, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of HCA Healthcare, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 23
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
112,455
+12.76%
|
$11,245,500
$100.99 P/Share
|
|
Apr 20
2021
|
Jon M Foster EVP and COO |
SELL
Open market or private sale
|
Direct |
5,504
-35.88%
|
$1,067,776
$194.9 P/Share
|
|
Apr 16
2021
|
Jon M Foster EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,496
-29.75%
|
$1,273,216
$196.93 P/Share
|
|
Apr 16
2021
|
Jon M Foster EVP and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+35.46%
|
$564,000
$47.97 P/Share
|
|
Mar 10
2021
|
Jon M Foster EVP and COO |
SELL
Open market or private sale
|
Direct |
5,432
-35.57%
|
$1,010,352
$186.18 P/Share
|
|
Mar 08
2021
|
Jon M Foster EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,568
-30.08%
|
$1,241,352
$189.21 P/Share
|
|
Mar 08
2021
|
Jon M Foster EVP and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+35.46%
|
$564,000
$47.97 P/Share
|
|
Mar 08
2021
|
Wayne Joseph Riley Director |
SELL
Open market or private sale
|
Direct |
1,650
-13.23%
|
$313,500
$190.0 P/Share
|
|
Feb 24
2021
|
Christopher F. Wyatt SVP & Controller |
SELL
Bona fide gift
|
Direct |
433
-1.54%
|
-
|
|
Feb 24
2021
|
Robert A Waterman SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
73,853
-5.59%
|
$12,998,128
$176.72 P/Share
|
|
Feb 23
2021
|
Jane D. Englebright SVP and Chief Nursing Officer |
SELL
Open market or private sale
|
Direct |
5,751
-26.38%
|
$1,000,674
$174.95 P/Share
|
|
Feb 19
2021
|
Jennifer Berres SVP & Chief Human Res. Officer |
SELL
Open market or private sale
|
Direct |
6,692
-66.44%
|
$1,177,792
$176.05 P/Share
|
|
Feb 19
2021
|
Christopher F. Wyatt SVP & Controller |
SELL
Open market or private sale
|
Direct |
3,200
-10.2%
|
$566,400
$177.06 P/Share
|
|
Feb 18
2021
|
Jennifer Berres SVP & Chief Human Res. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,301
-11.44%
|
$226,374
$174.61 P/Share
|
|
Feb 18
2021
|
Jennifer Berres SVP & Chief Human Res. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,306
+22.52%
|
-
|
|
Feb 18
2021
|
Phillip G Billington SVP-Internal Audit Services |
SELL
Payment of exercise price or tax liability
|
Direct |
3,164
-7.88%
|
$550,536
$174.61 P/Share
|
|
Feb 18
2021
|
Phillip G Billington SVP-Internal Audit Services |
BUY
Grant, award, or other acquisition
|
Direct |
10,146
+11.91%
|
-
|
|
Feb 18
2021
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,583
-13.15%
|
$971,442
$174.61 P/Share
|
|
Feb 18
2021
|
Michael S. Cuffe EVP and Chief Clinical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,186
+25.05%
|
-
|
|
Feb 18
2021
|
Jane D. Englebright SVP and Chief Nursing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,360
-20.31%
|
$410,640
$174.61 P/Share
|
|
Feb 18
2021
|
Jane D. Englebright SVP and Chief Nursing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,111
+41.11%
|
-
|
|
Feb 18
2021
|
Jon M Foster EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,384
-39.35%
|
$1,110,816
$174.61 P/Share
|
|
Feb 18
2021
|
Jon M Foster EVP and COO |
BUY
Grant, award, or other acquisition
|
Direct |
16,222
+50.0%
|
-
|
|
Feb 18
2021
|
Charles J Hall Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
6,384
-2.87%
|
$1,110,816
$174.61 P/Share
|
|
Feb 18
2021
|
Charles J Hall Group President |
BUY
Grant, award, or other acquisition
|
Direct |
16,222
+6.8%
|
-
|
|
Feb 18
2021
|
Samuel N Hazen CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
18,282
-5.77%
|
$3,181,068
$174.61 P/Share
|
|
Feb 18
2021
|
Samuel N Hazen CEO |
BUY
Grant, award, or other acquisition
|
Direct |
48,635
+13.3%
|
-
|
|
Feb 18
2021
|
A Bruce Moore Jr Group President - Service Line |
SELL
Payment of exercise price or tax liability
|
Direct |
5,583
-4.65%
|
$971,442
$174.61 P/Share
|
|
Feb 18
2021
|
A Bruce Moore Jr Group President - Service Line |
BUY
Grant, award, or other acquisition
|
Direct |
14,186
+10.57%
|
-
|
|
Feb 18
2021
|
Sandra L. Morgan SVP-Provider Relations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,567
-13.41%
|
$272,658
$174.61 P/Share
|
|
Feb 18
2021
|
Sandra L. Morgan SVP-Provider Relations |
BUY
Grant, award, or other acquisition
|
Direct |
6,091
+34.26%
|
-
|
|
Feb 18
2021
|
J William Morrow SVP - Finance and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,567
-21.93%
|
$272,658
$174.61 P/Share
|
|
Feb 18
2021
|
J William Morrow SVP - Finance and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
6,091
+46.02%
|
-
|
|
Feb 18
2021
|
P. Martin Paslick SVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,788
-27.1%
|
$833,112
$174.61 P/Share
|
|
Feb 18
2021
|
P. Martin Paslick SVP and CIO |
BUY
Grant, award, or other acquisition
|
Direct |
12,166
+40.78%
|
-
|
|
Feb 18
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,583
-8.18%
|
$971,442
$174.61 P/Share
|
|
Feb 18
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
14,186
+17.21%
|
-
|
|
Feb 18
2021
|
Deborah M Reiner SVP - Mktg. & Communications |
SELL
Payment of exercise price or tax liability
|
Direct |
1,567
-13.54%
|
$272,658
$174.61 P/Share
|
|
Feb 18
2021
|
Deborah M Reiner SVP - Mktg. & Communications |
BUY
Grant, award, or other acquisition
|
Direct |
6,091
+34.48%
|
-
|
|
Feb 18
2021
|
Bill B Rutherford CFO and EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
11,522
-23.12%
|
$2,004,828
$174.61 P/Share
|
|
Feb 18
2021
|
Bill B Rutherford CFO and EVP |
BUY
Grant, award, or other acquisition
|
Direct |
31,419
+38.67%
|
-
|
|
Feb 18
2021
|
Joseph A Sowell Iii SVP; Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,160
-20.36%
|
$549,840
$174.61 P/Share
|
|
Feb 18
2021
|
Joseph A Sowell Iii SVP; Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,147
+39.54%
|
-
|
|
Feb 18
2021
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Payment of exercise price or tax liability
|
Direct |
3,192
-14.18%
|
$555,408
$174.61 P/Share
|
|
Feb 18
2021
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
BUY
Grant, award, or other acquisition
|
Direct |
8,111
+26.49%
|
-
|
|
Feb 18
2021
|
Robert A Waterman SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
5,583
-1.56%
|
$971,442
$174.61 P/Share
|
|
Feb 18
2021
|
Robert A Waterman SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
14,186
+3.81%
|
-
|
|
Feb 18
2021
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,575
-20.87%
|
$448,050
$174.61 P/Share
|
|
Feb 18
2021
|
Kathleen M Whalen SVP & Chief Ethics Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,322
+29.68%
|
-
|
|
Feb 18
2021
|
Christopher F. Wyatt SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
2,360
-6.99%
|
$410,640
$174.61 P/Share
|